Group 1 - The core point of the article is that Wancheng Group (SZ 300972) held its 41st meeting of the fourth board of directors on December 15, 2025, where it reviewed the proposal to amend the "External Donation Management System" [1] - For the first half of 2025, Wancheng Group's revenue composition was 98.95% from snack retail and 1.05% from agricultural planting [1] - As of the report date, Wancheng Group's market capitalization was 33.7 billion yuan [1] Group 2 - The article also highlights concerns regarding the financial practices of Jiangsu Wuzhong, where related parties have questionable registration addresses, leading to shareholder inquiries about missing funds [1] - The annual sales of "Tongyan Needle" reached 300 million yuan, with a price point of 2,000 yuan per injection [1] - The company is facing potential delisting due to financial irregularities involving the Qian siblings [1]
万辰集团：12月15日召开董事会会议